Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND) Study

This observational study aims to understand how Alzheimer's disease (AD) develops from early stages to noticeable symptoms. Researchers are using special brain scans, including PET (positron emission tomography) and MRI (magnetic resonance imaging), to look for changes in the brain. They will use two investigational tracers, [11C]-Pittsburgh Compound B ([11C]PiB) and F 18 AV-1451 (Flortaucipir), which help detect amyloid and tau proteins that are linked to AD. The study hopes to identify markers of AD on these scans at different time points over five years. You may be eligible if you are over 18, participate in certain projects at Washington University, and have normal thinking abilities or early-stage AD. The current recruitment status is unclear.

Study design: This is an observational study with a planned enrollment of 650 participants. It is not specified if it is randomized or blinded.
What's involved: You would undergo PET, MRI, and CT imaging scans at baseline and at years 1, 2, and/or 3.
Compensation: Not stated in the trial record.
Follow-up: Participants will be followed for up to 5 years, with primary endpoints measured at this time.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)

Recruiting

Not specifiedAges 18+Observational

Tammie L. S. Benzinger, MD, PhD

~650 participants

Updated 2026-06-08 on ClinicalTrials.gov

What's tested:[11C]-Pittsburgh Compound B ([11C]PiB)F 18 AV-1451 (Flortaucipir)

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

AD Biomarkers seen on Amyloid PET at Baseline and Years 1, 2, and/or 3

Measured over 5 years

+3 more outcomes measured

Conditions

Alzheimer Disease

Where it's being run

1 sites across 1 states

Missouri1

Study leadership

Tammie Benzinger, MD, PhD · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine

Who to contact

Kelley Jackson, BA

[email protected]

314-362-1558

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Male or female, any race

Age \> 18 years

Participation in one of the ongoing projects affiliated with the Knight ADRC at Washington University and referred by the MAP staff and a Washington University physician.

Normal cognition or early-stage symptomatic AD

Willing and able to undergo study procedures.

Capacity to give informed consent and follow study procedures

Exclusion

Has any condition that, in the Investigator's opinion, could increase risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data (e.g., participants with severe chronic back pain might not be able to lie still during the scanning procedures);

Has hypersensitivity to either AV-1451 or PIB or any of its excipients;

Contraindications to PET, CT or MRI (e.g. electronic medical devices, inability to lie still for extended periods) that make it unsafe for the individual to participate;

Severe claustrophobia;

Currently pregnant or breast-feeding. Women must agree to avoid becoming pregnant and must agree to refrain from sexual activity or to use reliable contraceptive methods for 24 hours following administration of Flortaucipir injection;

Must not have participated in any clinical trial involving a study drug or device within the 30-days prior to study enrollment;

Must not participate in another drug or device study prior to the end of this study participation;

Current or recent (within 12 months prior to screening) participation in research studies involving radioactive agents such that the total research-related radiation dose to the participant in any given year would exceed the limits set forth in the U.S. Code of Federal Regulations (CFR) Title 21 Section 361.1.

What this trial measures

AD Biomarkers seen on Amyloid PET at Baseline and Years 1, 2, and/or 35 years
This Project aims to identify factors that signal the transition from asymptomatic (preclinical) to symptomatic Alzheimer disease (AD). This will be done by comparing imaging biomarkers seen with amyloid PET and the tracer C-11 PIB at baseline to imaging biomarkers collected longitudinally, at years 1, 2, and/or 3.
AD Biomarkers seen on Tau PET at Baseline and Years 1, 2, and/or 35 years
This Project aims to identify factors that signal the transition from asymptomatic (preclinical) to symptomatic Alzheimer disease (AD). This will be done by comparing imaging biomarkers seen with tau PET and the tracer Flortaucipir at baseline to imaging biomarkers collected longitudinally, at years 1, 2, and/or 3.
AD Biomarkers seen on MRI at Baseline and Years 1, 2, and/or 35 years
This Project aims to identify factors that signal the transition from asymptomatic (preclinical) to symptomatic Alzheimer disease (AD). This will be done by comparing imaging biomarkers seen with MRI at baseline to imaging biomarkers collected longitudinally, at years 1, 2, and/or 3.
Compare and Correlate Predictive Ability of Biomarkers Seen with Different Imaging Variables for Onset of Symptoms5 years
This project aims to compare and correlate the predictive ability of baseline values and rates of change of molecular biomarkers of AD for onset of AD symptoms with other variables. Variables obtained in this project include: 1) volumetric MRI, 2) MRI measures of vascular burden, 3) functional MRI, 4) amyloid PET, and 5) tau PET.

Trialytics